Fetal Aortic Valvuloplasty for Evolving Hypoplastic Left Heart Syndrome

NCT ID: NCT06342999

Last Updated: 2025-07-17

Basic Information

• Recruitment Status: ENROLLING_BY_INVITATION
• Clinical Phase: NA
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-01-01
• Study Completion Date: 2036-07-31

Brief Summary

The purpose of this research is to investigate the best way to manage evolving hypoplastic left heart syndrome (HLHS).

Detailed Description

The condition occurs when part of the heart doesn't develop properly so the heart is not able to pump blood around the body effectively. Babies born with this condition require surgery and are often left with a lifelong heart disability. A number of babies with this condition will die during pregnancy or within the first year of life (approximately 10-40%). We are investigating a treatment given during pregnancy in which a balloon is used to increase the size of the baby's aortic valve. The aortic valve function is to allow easy flow from the heart to the body and prevent blood from returning to the heart (regurgitation). This is called fetal aortic valvuloplasty. A number of studies have shown promising results, including a higher of the baby surviving with both sides of the heart functioning (as opposed to only the right side), this may also lead to longer survival with a better quality of life. However, we do not have enough information to say this is always the best way to manage the condition. Currently, parents of babies with this condition, who meet certain eligibility criteria, are offered fetal aortic valvuloplasty during pregnancy. The alternative option is not to intervene during pregnancy but instead monitor the baby with regular ultrasounds. We call this conservative management.

Conditions

Hypoplastic Left Heart Syndrome

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Intervention Group: Fetal Aortic Valvuloplasty

Women diagnosed with HLHS will undergo fetal aortic valvuloplasty between 21 and 29 weeks gestation.

Group Type: EXPERIMENTAL

Fetal Aortic Valvuloplasty Procedure

Intervention Type: PROCEDURE

Treatment given during pregnancy in which a balloon is used to increase the size of the baby's aortic valve in vitro.

Emerge Monorail and Over-The-Wire PTCA Dilatation Catheter

Intervention Type: DEVICE

Balloon Catheter

Trek RX and Mini Trek RX Coronary Dilatation Catheter

Intervention Type: DEVICE

Coronary Dilation Catheter

Control Group: Expectant Management

Women diagnosed with HLHS will undergo expectant management with postnatal surgery.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Fetal Aortic Valvuloplasty Procedure

Treatment given during pregnancy in which a balloon is used to increase the size of the baby's aortic valve in vitro.

Intervention Type: PROCEDURE

Emerge Monorail and Over-The-Wire PTCA Dilatation Catheter

Balloon Catheter

Intervention Type: DEVICE

Trek RX and Mini Trek RX Coronary Dilatation Catheter

Coronary Dilation Catheter

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Pregnant women 18-45 years of age.
• Gestational age between 21 0/7 and 29 6/7 weeks of gestation
• The mother must be healthy enough to undergo surgery.
• The individual being enrolled must be able to provide informed consent.
• Dominant cardiac defect is valvar
• Evolving hypoplastic left heart syndrome defined as depressed left ventricle systolic and at least one of the following:

• Retrograde flow in the transverse aortic arch
• Two of the following: (1) left to right flow across the atrial septum (bulging of the septum left to right in cases of intact atrial septum); (2) monophasic mitral valve inflow; (3) bidirectional flow in the pulmonary veins.
• Potential for a technically successful and postnatal biventricular outcome defined as left ventricle long axis Z-score equal or greater than -2 PLUS at least 4 of the following 5 criteria:

• Left ventricle long axis Z-score more than zero
• Left ventricle short axis Z-score more than zero
• Aortic annulus Z-score more than -3.5
• Mitral valve annulus Z-score more than -2
• Left ventricle generating a maximal instantaneous gradient (MIG) equal or greater than 20 mmHg (or by mitral regurgitation jet greater than or equal to 20 mmHg).

Exclusion Criteria

• Patient is less than 18 years of age or more than 45 years of age.
• Contraindication to anesthesia or surgery
• Preterm labor or cervical length <20 mm at enrollement or uterine anomaly strongly predisposing to preterm delivery.
• Other fetal anomalies that significantly impact fetal/neonatal survival (e.g., congenital diaphragmatic hernia, bilateral renal agenesis, etc.)
• Fetal aneuploidy and pathogenic findings on Karyotype or Microarray that impact significantly the fetal/neonatal survival.
• Cases with all the following criteria:

• Left ventricle pressure ≤ 47 mmHg
• MV dimension Z-score < 0.1
• MV inflow time Z-score < -2

• Maximum Eligible Age: 45 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Mauro H. Schenone

OTHER

Sponsor Role: lead

Responsible Party

Mauro H. Schenone

Regulatory Sponsor and Principal Investigator

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Mauro Schenone, MD

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic

Locations

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Countries

United States

Related Links

https://www.mayo.edu/research/clinical-trials

Mayo Clinic Clinical Trials

Other Identifiers

22-012399

Identifier Type: -

Identifier Source: org_study_id